Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-06-14

Clinical Trial Update: Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase II trial of BKM120 in recurrent glioblastoma has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BKM120 (Buparlisib)

Snippet

Sponsor: Patrick Y. Wen, MD | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2017-06-14